CRANBURY, N.J.--(BUSINESS WIRE)--Physicians’ Education Resource® (PER®), the nation’s leading resource for oncology and hematology continuing medical education (CME), will present a live tumor board titled “Real-World Evidence to Inform Treatment and Management of ER+ Metastatic Breast Cancer” on Wednesday, Dec. 12, at 3:00 p.m. EST. The webcast will be chaired by Hope S. Rugo, M.D., FASCO, clinical professor in the department of medicine (hematology/oncology) and director of the breast oncology clinical trials program at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center.
“Often times in discussing new treatments in cancer care, discussion is limited to clinical trial efficacy and safety data,” said Phil Talamo, president of PER® “We are excited to present this new CME-certified live webcast activity format that incorporates recent real-world data to ensure that clinicians can better apply novel strategies to the care of their patients, and allow for live interaction with our expert faculty.”
Faculty presenters for the live tumor board include:
- Angela M. DeMichele, M.D., MSCE, Jill and Allan Miller Professor in Breast Cancer Excellence and professor of medicine and epidemiology at the University of Pennsylvania School of Medicine and co-leader of the Abramson Cancer Center breast cancer research program.
- Komal Jhaveri M.D., FACP, medical oncologist, Memorial Sloan Kettering Cancer Center.
- Joseph A. Sparano, M.D., professor in the departments of medicine and obstetrics & gynecology and women’s health at Albert Einstein College of Medicine, associate director of clinical research at the Albert Einstein Cancer Center and associate chairman of clinical research in the department of oncology at Montefiore Medical Center.
This live CME-certified interactive webcast is designed to update oncology health care professionals who participate in the multidisciplinary treatment of patients with estrogen receptor-positive (ER+) metastatic breast cancer by providing expert guidance, interpretation and insight on the importance and impact of CDK4/6 inhibitors. Attendees will have the opportunity to network with top clinicians and scientists, apply novel management strategies to their practice to improve patient outcomes, and participate in an exciting case-based format about current challenges and controversies in the treatment of ER+ breast cancer.
For more information and to register for the live webcast, click here.
About Physicians’ Education Resource® (PER®)
Since 1995, PER® has been dedicated to advancing cancer care through professional education and now furthers patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER® initiated CME programming in the cardiovascular and endocrinology areas and continues to grow its therapeutic reach outside of oncology. While continuing to expand into topics outside of oncology, PER® remains the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. By the end of 2018, PER® will have developed and implemented 21 historic annual legacy conferences in the United States and Europe, along with many renowned online learning formats. PER® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER® is part of the Cranbury, New Jersey-based MJH Associates Inc. family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.